GlaxoSmithKline Pharmaceuticals Limited — Board Meeting, 13-05-2025: Outcome of Board Meeting

GlaxoSmithKline Pharmaceuticals has announced a board meeting approving its audited consolidated financial results for the quarter and year ended March 31, 2025. The company posted a strong profit after tax of Rs. 927.58 Cr, up from Rs. 589.96 Cr, supported by revenue growth to Rs. 3895.14 Cr and tight cost control. A final dividend of Rs. 42 per share has been declared, higher than last year’s Rs. 32. Dr. Sunita Maheshwari was re-appointed as Independent Director, and Parikh & Associates named Secretarial Auditor for five years starting FY 2025-26.